Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
|Articles|June 23, 2015
Colleen O'Leary on the Importance of Navigation for Patients With Head and Neck Cancer
Author(s)Colleen M. O'Leary, RN, MSN, AOCNS
Colleen M. O'Leary, RN, MSN, AOCNS, from The James Cancer Hospital, The Ohio State University, discusses the importance of navigation for patients with head and neck cancer.
Advertisement
Colleen M. O'Leary, RN, MSN, AOCNS, clinical nurse specialist, head & neck cancers, coordinator, nursing evidence-based practice, The James Cancer Hospital, The Ohio State University, discusses the importance of navigation for patients with head and neck cancer.
Advertisement
Related to this article
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
2
What Oncology Nurses Need to Know About ADCs in Breast Cancer
3
Male Breast Cancer: Managing Endocrine Therapy and Survivorship Care
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
5